Non-Traditional Antibacterial Screening Approaches for the Identification of Novel Inhibitors of the Glyoxylate Shunt in Gram-Negative Pathogens

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Fahnoe, Kelly C ^a,b   Flanagan, Mark E ^a   Gibson, Glenn ^a,c   Shanmugasundaram, Veerabahu ^a   Che, Ye ^a   Tomaras, Andrew P ^a  

^a PFIZER INC   (United States)

^b Celgene Avilomics Research   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GLYOXYLIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PROCESS OPTIMIZATION; PSEUDOMONAS AERUGINOSA; STRUCTURE ANALYSIS;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLYOXYLATES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOCITRATE LYASE; MALATE SYNTHASE; METABOLIC NETWORKS AND PATHWAYS; PSEUDOMONAS AERUGINOSA; SEQUENCE DELETION; SMALL MOLECULE LIBRARIES;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84871156127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051732     Document Type: Article

References (39)

1. Levy SB (1997) Antibiotic resistance: an ecological imbalance. Ciba Found Symp 207: 1-9; discussion 9-14.
2. Barbosa TM, Levy SB, (2000) The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 3: 303-311.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
4. Silver LL, (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
6. Svensson A, Larsson A, Emtenas H, Hedenstrom M, Fex T, et al. (2001) Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2: 915-918.
7. Armstrong GD, Rowe PC, Goodyer P, Orrbine E, Klassen TP, et al. (1995) A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 171: 1042-1045.
8. Hu JF, Garo E, Goering MG, Pasmore M, Yoo HD, et al. (2006) Bacterial biofilm inhibitors from Diospyros dendo. J Nat Prod 69: 118-120.
9. Rogers SA, Whitehead DC, Mullikin T, Melander C, (2010) Synthesis and bacterial biofilm inhibition studies of ethyl N-(2-phenethyl) carbamate derivatives. Org Biomol Chem 8: 3857-3859.
10. Smith KM, Bu Y, Suga H, (2003) Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol 10: 81-89.
11. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, et al. (2003) Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 22: 3803-3815.
12. Umland TC, Schultz LW, MacDonald U, Beanan JM, Olson R, et al. (2012) In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media. MBio 3.
13. Miller RM, Tomaras AP, Barker AP, Voelker DR, Chan ED, et al. (2008) Pseudomonas aeruginosa twitching motility-mediated chemotaxis towards phospholipids and fatty acids: specificity and metabolic requirements. J Bacteriol 190: 4038-4049.
14. Hearn EM, Patel DR, Lepore BW, Indic M, van den Berg B, (2009) Transmembrane passage of hydrophobic compounds through a protein channel wall. Nature 458: 367-370.
15. Black PN, DiRusso CC, (1994) Molecular and biochemical analyses of fatty acid transport, metabolism, and gene regulation in Escherichia coli. Biochim Biophys Acta 1210: 123-145.
16. Ogawa W, Li DW, Yu P, Begum A, Mizushima T, et al. (2005) Multidrug resistance in Klebsiella pneumoniae MGH78578 and cloning of genes responsible for the resistance. Biol Pharm Bull 28: 1505-1508.
17. CLSI (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Clinical Laboratory Standards Institute (CLSI) M07.
18. Schweizer HP, Hoang TT, (1995) An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene 158: 15-22.
19. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP, (1998) A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212: 77-86.
20. Figurski DH, Helinski DR, (1979) Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in trans. Proceedings of the National Academy of Sciences 76: 1648-1652.
21. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, et al. (2005) Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73: 2504-2514.
22. Schloss JV, Cleland WW, (1982) Inhibition of isocitrate lyase by 3-nitropropionate, a reaction-intermediate analogue. Biochemistry 21: 4420-4427.
23. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
24. Chell RM, Sundaram TK, Wilkinson AE, (1978) Isolation and characterization of isocitrate lyase from a thermophilic Bacillus sp. Biochem J 173: 165-177.
25. Khan AS, Van Driessche E, Kanarek L, Beeckmans S, (1993) Purification of the glyoxylate cycle enzyme malate synthase from maize (Zea mays L.) and characterization of a proteolytic fragment. Protein Expr Purif 4: 519-528.
26. Sharma V, Sharma S, Hoener zu Bentrup K, McKinney JD, Russell DG, et al. (2000) Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 7: 663-668.
27. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, et al. (2003) Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 278: 1735-1743.
28. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, et al. (2012) The Pfam protein families database. Nucleic Acids Res 40: D290-301.
29. Sali A, Blundell TL, (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
30. Bowie JU, Luthy R, Eisenberg D, (1991) A method to identify protein sequences that fold into a known three-dimensional structure. Science 253: 164-170.
31. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R, (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553.
32. Dunn MF, Ramirez-Trujillo JA, Hernandez-Lucas I, (2009) Major roles of isocitrate lyase and malate synthase in bacterial and fungal pathogenesis. Microbiology 155: 3166-3175.
33. Anstrom DM, Remington SJ, (2006) The product complex of M. tuberculosis malate synthase revisited. Protein Sci 15: 2002-2007.
34. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, et al. (2000) Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735-738.
35. Shingnapurkar D, Dandawate P, Anson CE, Powell AK, Afrasiabi Z, et al. (2012) Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors. Bioorg Med Chem Lett 22: 3172-3176.
36. Lindsey TL, Hagins JM, Sokol PA, Silo-Suh LA, (2008) Virulence determinants from a cystic fibrosis isolate of Pseudomonas aeruginosa include isocitrate lyase. Microbiology 154: 1616-1627.
37. Hoboth C, Hoffmann R, Eichner A, Henke C, Schmoldt S, et al. (2009) Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 200: 118-130.
38. Hagins JM, Scoffield J, Suh SJ, Silo-Suh L, (2011) Malate synthase expression is deregulated in the Pseudomonas aeruginosa cystic fibrosis isolate FRD1. Can J Microbiol 57: 186-195.
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.